MUC1 and metastatic cancer

References

• Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12:895 - 904; http://dx.doi.org/10.1038/nm1469; PMID: 16892035
   PubMed Web of Science ®Google Scholar
• Baldus SE, Engelmann K, Hanisch FG. MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 2004; 41:189 - 231; http://dx.doi.org/10.1080/10408360490452040; PMID: 15270554
   PubMed Web of Science ®Google Scholar
• Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001; 6:339 - 53; http://dx.doi.org/10.1023/A:1011379725811; PMID: 11547902
   PubMed Web of Science ®Google Scholar
• Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 2010; 29:2893 - 904; http://dx.doi.org/10.1038/onc.2010.87; PMID: 20348949
   PubMed Web of Science ®Google Scholar
• Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 2012; In press http://dx.doi.org/10.1038/onc.2012.158; PMID: 22580612
   PubMed Web of Science ®Google Scholar
• Singh PK, Hollingsworth MA. Cell surface-associated mucins in signal transduction. Trends Cell Biol 2006; 16:467 - 76; http://dx.doi.org/10.1016/j.tcb.2006.07.006; PMID: 16904320
   PubMed Web of Science ®Google Scholar
• Rahn JJ, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001; 91:1973 - 82; http://dx.doi.org/10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A; PMID: 11391575
   PubMed Web of Science ®Google Scholar
• Lavrsen K, Madsen CB, Rasch MG, Woetmann A, Odum N, Mandel U, et al. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj J 2012; In press http://dx.doi.org/10.1007/s10719-012-9437-7; PMID: 22878593
   PubMed Web of Science ®Google Scholar
• McGuckin MA, Walsh MD, Hohn BG, Ward BG, Wright RG. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol 1995; 26:432 - 9; http://dx.doi.org/10.1016/0046-8177(95)90146-9; PMID: 7705823
   PubMed Web of Science ®Google Scholar
• Greenberg R, Barnea Y, Schneebaum S, Kashtan H, Kaplan O, Skornik Y. Detection of hepatocyte growth factor/scatter factor receptor (c-Met) and MUC1 from the axillary fluid drainage in patients after breast cancer surgery. Isr Med Assoc J 2003; 5:649 - 52; PMID: 14509156
   PubMed Web of Science ®Google Scholar
• Schroeder JA, Adriance MC, Thompson MC, Camenisch TD, Gendler SJ. MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 2003; 22:1324 - 32; http://dx.doi.org/10.1038/sj.onc.1206291; PMID: 12618757
   PubMed Web of Science ®Google Scholar
• Park S, Ahn HK, Park LC, Hwang DW, Ji JH, Maeng CH, et al. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer. Oncology 2012; 82:180 - 7; http://dx.doi.org/10.1159/000336081; PMID: 22433564
   PubMed Web of Science ®Google Scholar
• Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, et al. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol Immunother 2011; 60:975 - 84; http://dx.doi.org/10.1007/s00262-011-1010-x; PMID: 21461842
   PubMed Web of Science ®Google Scholar
• Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC, et al. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol 2007; 105:695 - 702; http://dx.doi.org/10.1016/j.ygyno.2007.02.004; PMID: 17368732
   PubMed Web of Science ®Google Scholar
• Dong Y, Walsh MD, Cummings MC, Wright RG, Khoo SK, Parsons PG, et al. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J Pathol 1997; 183:311 - 7; http://dx.doi.org/10.1002/(SICI)1096-9896(199711)183:3<311::AID-PATH917>3.0.CO;2-2; PMID: 9422987
   PubMed Web of Science ®Google Scholar
• Cozzi PJ, Wang J, Delprado W, Perkins AC, Allen BJ, Russell PJ, et al. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis 2005; 22:565 - 73; http://dx.doi.org/10.1007/s10585-005-5376-z; PMID: 16475027
   PubMed Web of Science ®Google Scholar
• Retterspitz MF, Mönig SP, Schreckenberg S, Schneider PM, Hölscher AH, Dienes HP, et al. Expression of beta-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis. Anticancer Res 2010; 30:4635 - 41; PMID: 21115917
   PubMed Web of Science ®Google Scholar
• Yonezawa S, Kitajima S, Higashi M, Osako M, Horinouchi M, Yokoyama S, et al. A novel anti-MUC1 antibody against the MUC1 cytoplasmic tail domain: use in sensitive identification of poorly differentiated cells in adenocarcinoma of the stomach. Gastric Cancer 2012; 15:370 - 81; http://dx.doi.org/10.1007/s10120-011-0125-2; PMID: 22237656
   PubMed Web of Science ®Google Scholar
• Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A, Yoshitomi H, et al. Similarities and differences between intraductal papillary tumors of the bile duct with and without macroscopically visible mucin secretion. Am J Surg Pathol 2011; 35:512 - 21; http://dx.doi.org/10.1097/PAS.0b013e3182103f36; PMID: 21412069
   PubMed Web of Science ®Google Scholar
• Zhang K, Tang W, Qu X, Guo Q, Inagaki Y, Seyama Y, et al. KL-6 mucin in metastatic liver cancer tissues from primary colorectal carcinoma. Hepatogastroenterology 2009; 56:960 - 3; PMID: 19760920
   PubMed Web of Science ®Google Scholar
• Mizumoto M, Honjo G, Kobashi Y, Awane M, Matsusue S. Molecular profile of apomucin and p53 protein as predictors of malignancy in intraductal papillary mucinous neoplasms of the pancreas. Hepatogastroenterology 2011; 58:1791 - 5; PMID: 22086702
   PubMed Web of Science ®Google Scholar
• Xu H, Inagaki Y, Seyama Y, Du G, Wang F, Kokudo N, et al. Expression of KL-6/MUC1 in pancreatic cancer tissues and its potential involvement in tumor metastasis. Oncol Rep 2011; 26:371 - 6; PMID: 21617869
   PubMed Web of Science ®Google Scholar
• Hamada T, Nomura M, Kamikawa Y, Yamada N, Batra SK, Yonezawa S, et al. DF3 epitope expression on MUC1 mucin is associated with tumor aggressiveness, subsequent lymph node metastasis, and poor prognosis in patients with oral squamous cell carcinoma. Cancer 2012; 118:5251 - 64; http://dx.doi.org/10.1002/cncr.27542; PMID: 22434549
   PubMed Web of Science ®Google Scholar
• Liu XY, Chen G, Wang Z, Liu FY. Clinical significance of detecting mucin 1 mRNA in diagnosing occult lymph node micrometastasis in esophageal cancer patients. Ai Zheng 2007; 26:194 - 9; PMID: 17298752
   PubMedGoogle Scholar
• Leroy X, Zerimech F, Zini L, Copin MC, Buisine MP, Gosselin B, et al. MUC1 expression is correlated with nuclear grade and tumor progression in pT1 renal clear cell carcinoma. Am J Clin Pathol 2002; 118:47 - 51; http://dx.doi.org/10.1309/1F99-BPDY-7DHH-9G97; PMID: 12109855
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Komoda M, Yamada Y, Yonezawa S, Tsutsumida H, Nagai K, et al. Aberrant overexpression of membrane-associated mucin contributes to tumor progression in adult T-cell leukemia/lymphoma cells. Leuk Lymphoma 2011; 52:1108 - 17; http://dx.doi.org/10.3109/10428194.2011.559671; PMID: 21599593
   PubMed Web of Science ®Google Scholar
• Kaira K, Murakami H, Serizawa M, Koh Y, Abe M, Ohde Y, et al. MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma. Virchows Arch 2011; 458:615 - 20; http://dx.doi.org/10.1007/s00428-011-1041-x; PMID: 21253760
   PubMed Web of Science ®Google Scholar
• Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 2012; 9:016003; http://dx.doi.org/10.1088/1478-3975/9/1/016003; PMID: 22306768
   PubMed Web of Science ®Google Scholar
• Sanislo L, Vertakova-Krakovska B, Kuliffay P, Brtko J, Galbava A, Galbavy S. Detection of circulating tumor cells in metastatic breast cancer patients. Endocr Regul 2011; 45:113 - 24; http://dx.doi.org/10.4149/endo_2011_03_113; PMID: 21793623
   PubMedGoogle Scholar
• Deng G, Herrler M, Burgess D, Manna E, Krag D, Burke JF. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res 2008; 10:R69; http://dx.doi.org/10.1186/bcr2131; PMID: 18687126
   PubMed Web of Science ®Google Scholar
• Sha MY, Xu H, Natan MJ, Cromer R. Surface-enhanced Raman scattering tags for rapid and homogeneous detection of circulating tumor cells in the presence of human whole blood. J Am Chem Soc 2008; 130:17214 - 5; http://dx.doi.org/10.1021/ja804494m; PMID: 19053187
   PubMed Web of Science ®Google Scholar
• de Albuquerque A, Kaul S, Breier G, Krabisch P, Fersis N. Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine. Breast Care (Basel) 2012; 7:7 - 12; http://dx.doi.org/10.1159/000336548; PMID: 22553466
   PubMed Web of Science ®Google Scholar
• de Albuquerque A, Kubisch I, Breier G, Stamminger G, Fersis N, Eichler A, et al. Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. Oncology 2012; 82:3 - 10; http://dx.doi.org/10.1159/000335479; PMID: 22270149
   PubMed Web of Science ®Google Scholar
• de Albuquerque A, Kubisch I, Ernst D, Breier G, Stamminger G, Fersis N, et al. Development of a molecular multimarker assay for the analysis of circulating tumor cells in adenocarcinoma patients. Clin Lab 2012; 58:373 - 84; PMID: 22783565
   PubMed Web of Science ®Google Scholar
• Aktas B, Müller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol 2011; 122:356 - 60; http://dx.doi.org/10.1016/j.ygyno.2011.04.039; PMID: 21605893
   PubMed Web of Science ®Google Scholar
• Thie H, Toleikis L, Li J, von Wasielewski R, Bastert G, Schirrmann T, et al. Rise and fall of an anti-MUC1 specific antibody. PLoS One 2011; 6:e15921; http://dx.doi.org/10.1371/journal.pone.0015921; PMID: 21264246
   PubMed Web of Science ®Google Scholar
• Kruit A, Gerritsen WB, Pot N, Grutters JC, van den Bosch JM, Ruven HJ. CA 15-3 as an alternative marker for KL-6 in fibrotic lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27:138 - 46; PMID: 21319596
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Shering S, Sherry F, McDermott E, O’Higgins N. CA 15-3: a prognostic marker in breast cancer. Int J Biol Markers 2000; 15:330 - 3; PMID: 11192829
   PubMed Web of Science ®Google Scholar
• González-Sistal A, Arias JI, Ruibal A. CA 15-3 serum levels in patients with ductal breast carcinoma: relationship with clinicopathological parameters and tumor markers. Int J Biol Markers 2012; 27:47 - 52; http://dx.doi.org/10.5301/JBM.2011.8591; PMID: 21928245
   PubMed Web of Science ®Google Scholar
• Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kokudo N, Sugawara Y, et al. Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol 2006; 12:54 - 9; PMID: 16440417
   PubMed Web of Science ®Google Scholar
• Kaira K, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, et al. Depolarized MUC1 expression is closely associated with hypoxic markers and poor outcome in resected non-small cell lung cancer. Int J Surg Pathol 2012; 20:223 - 32; http://dx.doi.org/10.1177/1066896911429296; PMID: 22108499
   PubMed Web of Science ®Google Scholar
• Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005; 18:1295 - 304; http://dx.doi.org/10.1038/modpathol.3800445; PMID: 15976813
   PubMed Web of Science ®Google Scholar
• Ghosh M, Kamma H, Kawamoto T, Koike N, Miwa M, Kapoor VK, et al. MUC 1 core protein as a marker of gallbladder malignancy. Eur J Surg Oncol 2005; 31:891 - 6; http://dx.doi.org/10.1016/j.ejso.2005.03.008; PMID: 15922536
   PubMed Web of Science ®Google Scholar
• Spicer AP, Rowse GJ, Lidner TK, Gendler SJ. Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem 1995; 270:30093 - 101; http://dx.doi.org/10.1074/jbc.270.50.30093; PMID: 8530414
   PubMed Web of Science ®Google Scholar
• Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12:954 - 61; PMID: 1312220
   PubMed Web of Science ®Google Scholar
• Schroeder JA, Masri AA, Adriance MC, Tessier JC, Kotlarczyk KL, Thompson MC, et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004; 23:5739 - 47; http://dx.doi.org/10.1038/sj.onc.1207713; PMID: 15221004
   PubMed Web of Science ®Google Scholar
• Sandgren EP, Schroeder JA, Qui TH, Palmiter RD, Brinster RL, Lee DC. Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res 1995; 55:3915 - 27; PMID: 7641211
   PubMed Web of Science ®Google Scholar
• Pochampalli MR, Bitler BG, Schroeder JA. Transforming growth factor alpha dependent cancer progression is modulated by Muc1. Cancer Res 2007; 67:6591 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-06-4518; PMID: 17638868
   PubMed Web of Science ®Google Scholar
• Besmer DM, Curry JM, Roy LD, Tinder TL, Sahraei M, Schettini J, et al. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res 2011; 71:4432 - 42; http://dx.doi.org/10.1158/0008-5472.CAN-10-4439; PMID: 21558393
   PubMed Web of Science ®Google Scholar
• Finn OJ, Gantt KR, Lepisto AJ, Pejawar-Gaddy S, Xue J, Beatty PL. Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas. Immunol Res 2011; 50:261 - 8; http://dx.doi.org/10.1007/s12026-011-8214-1; PMID: 21717081
   PubMed Web of Science ®Google Scholar
• Rye PD, Norum L, Olsen DR, Garman-Vik S, Kaul S, Fodstad O. Brain metastasis model in athymic nude mice using a novel MUC1-secreting human breast-cancer cell line, MA11. Int J Cancer 1996; 68:682 - 7; http://dx.doi.org/10.1002/(SICI)1097-0215(19961127)68:5<682::AID-IJC20>3.0.CO;2-2; PMID: 8938153
   PubMed Web of Science ®Google Scholar
• Gao J, McConnell MJ, Yu B, Li J, Balko JM, Black EP, et al. MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol 2009; 35:337 - 45; PMID: 19578748
   PubMed Web of Science ®Google Scholar
• Tsutsumida H, Swanson BJ, Singh PK, Caffrey TC, Kitajima S, Goto M, et al. RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clin Cancer Res 2006; 12:2976 - 87; http://dx.doi.org/10.1158/1078-0432.CCR-05-1197; PMID: 16707592
   PubMed Web of Science ®Google Scholar
• Aubert S, Fauquette V, Hémon B, Lepoivre R, Briez N, Bernard D, et al. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res 2009; 69:5707 - 15; http://dx.doi.org/10.1158/0008-5472.CAN-08-4905; PMID: 19549898
   PubMed Web of Science ®Google Scholar
• Mikami Y, Hisatsune A, Tashiro T, Isohama Y, Katsuki H. Hypoxia enhances MUC1 expression in a lung adenocarcinoma cell line. Biochem Biophys Res Commun 2009; 379:1060 - 5; http://dx.doi.org/10.1016/j.bbrc.2009.01.002; PMID: 19141292
   PubMed Web of Science ®Google Scholar
• Gaemers IC, Vos HL, Volders HH, van der Valk SW, Hilkens J. A stat-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J Biol Chem 2001; 276:6191 - 9; http://dx.doi.org/10.1074/jbc.M009449200; PMID: 11084045
   PubMed Web of Science ®Google Scholar
• Berclaz G, Altermatt HJ, Rohrbach V, Siragusa A, Dreher E, Smith PD. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int J Oncol 2001; 19:1155 - 60; PMID: 11713584
   PubMed Web of Science ®Google Scholar
• Xia L, Wang L, Chung AS, Ivanov SS, Ling MY, Dragoi AM, et al. Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J Biol Chem 2002; 277:30716 - 23; http://dx.doi.org/10.1074/jbc.M202823200; PMID: 12070153
   PubMed Web of Science ®Google Scholar
• Khodarev N, Ahmad R, Rajabi H, Pitroda S, Kufe T, McClary C, et al. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene 2010; 29:920 - 9; http://dx.doi.org/10.1038/onc.2009.391; PMID: 19915608
   PubMed Web of Science ®Google Scholar
• Pochampalli MR, el Bejjani RM, Schroeder JA. MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene 2007; 26:1693 - 701; http://dx.doi.org/10.1038/sj.onc.1209976; PMID: 16983337
   PubMed Web of Science ®Google Scholar
• Li Y, Kuwahara H, Ren J, Wen G, Kufe D. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem 2001; 276:6061 - 4; http://dx.doi.org/10.1074/jbc.C000754200; PMID: 11152665
   PubMed Web of Science ®Google Scholar
• Rajabi H, Joshi MD, Jin C, Ahmad R, Kufe D. Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cells. Prostate 2011; 71:1299 - 308; PMID: 21308711
   PubMed Web of Science ®Google Scholar
• Mitchell S, Abel P, Madaan S, Jeffs J, Chaudhary K, Stamp G, et al. Androgen-dependent regulation of human MUC1 mucin expression. Neoplasia 2002; 4:9 - 18; http://dx.doi.org/10.1038/sj.neo.7900194; PMID: 11922395
   PubMed Web of Science ®Google Scholar
• Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, Abba MC. MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 2010; 201:102 - 10; http://dx.doi.org/10.1016/j.cancergencyto.2010.05.015; PMID: 20682394
   PubMed Web of Science ®Google Scholar
• Rajabi H, Jin C, Ahmad R, McClary C, Joshi MD, Kufe D. MUCIN 1 ONCOPROTEIN EXPRESSION IS SUPPRESSED BY THE miR-125b ONCOMIR. Genes Cancer 2010; 1:62 - 8; http://dx.doi.org/10.1177/1947601909357933; PMID: 20729973
   PubMedGoogle Scholar
• O’Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 2010; 12:201; http://dx.doi.org/10.1186/bcr2484; PMID: 20346098
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Mo YY. miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res 2010; 2:170 - 80; PMID: 20407606
   PubMed Web of Science ®Google Scholar
• Luo X, Burwinkel B, Tao S, Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer?. Cancer Epidemiol Biomarkers Prev 2011; 20:1272 - 86; http://dx.doi.org/10.1158/1055-9965.EPI-11-0035; PMID: 21551242
   PubMed Web of Science ®Google Scholar
• Regimbald LH, Pilarski LM, Longenecker BM, Reddish MA, Zimmermann G, Hugh JC. The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 1996; 56:4244 - 9; PMID: 8797599
   PubMed Web of Science ®Google Scholar
• Ciborowski P, Finn OJ. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis. Clin Exp Metastasis 2002; 19:339 - 45; http://dx.doi.org/10.1023/A:1015590515957; PMID: 12090474
   PubMed Web of Science ®Google Scholar
• Geng Y, Yeh K, Takatani T, King MR. Three to Tango: MUC1 as a Ligand for Both E-Selectin and ICAM-1 in the Breast Cancer Metastatic Cascade. Front Oncol 2012; 2:76; http://dx.doi.org/10.3389/fonc.2012.00076; PMID: 22866263
   PubMedGoogle Scholar
• Orr FW, Wang HH, Lafrenie RM, Scherbarth S, Nance DM. Interactions between cancer cells and the endothelium in metastasis. J Pathol 2000; 190:310 - 29; http://dx.doi.org/10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; PMID: 10685065
   PubMed Web of Science ®Google Scholar
• Shen Q, Rahn JJ, Zhang J, Gunasekera N, Sun X, Shaw AR, et al. MUC1 initiates Src-CrkL-Rac1/Cdc42-mediated actin cytoskeletal protrusive motility after ligating intercellular adhesion molecule-1. Mol Cancer Res 2008; 6:555 - 67; http://dx.doi.org/10.1158/1541-7786.MCR-07-2033; PMID: 18403635
   PubMed Web of Science ®Google Scholar
• Rahn JJ, Chow JW, Horne GJ, Mah BK, Emerman JT, Hoffman P, et al. MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis 2005; 22:475 - 83; http://dx.doi.org/10.1007/s10585-005-3098-x; PMID: 16320110
   PubMed Web of Science ®Google Scholar
• Aleshin A, Finn RS. SRC: a century of science brought to the clinic. Neoplasia 2010; 12:599 - 607; PMID: 20689754
   PubMed Web of Science ®Google Scholar
• Horn G, Gaziel A, Wreschner DH, Smorodinsky NI, Ehrlich M. ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1. Exp Cell Res 2009; 315:1490 - 504; http://dx.doi.org/10.1016/j.yexcr.2009.02.011; PMID: 19245809
   PubMed Web of Science ®Google Scholar
• Yao M, Zhang W, Zhang Q, Xing L, Xu A, Liu Q, et al. Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways. Lung 2011; 189:453 - 60; http://dx.doi.org/10.1007/s00408-011-9327-y; PMID: 21959954
   PubMed Web of Science ®Google Scholar
• Chaika NV, Gebregiworgis T, Lewallen ME, Purohit V, Radhakrishnan P, Liu X, et al. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci U S A 2012; 109:13787 - 92; http://dx.doi.org/10.1073/pnas.1203339109; PMID: 22869720
   PubMed Web of Science ®Google Scholar
• Grosfeld A, Andre J, Hauguel-De Mouzon S, Berra E, Pouyssegur J, Guerre-Millo M. Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J Biol Chem 2002; 277:42953 - 7; http://dx.doi.org/10.1074/jbc.M206775200; PMID: 12215445
   PubMed Web of Science ®Google Scholar
• Scheid A, Wenger RH, Schäffer L, Camenisch I, Distler O, Ferenc A, et al. Physiologically low oxygen concentrations in fetal skin regulate hypoxia-inducible factor 1 and transforming growth factor-beta3. FASEB J 2002; 16:411 - 3; PMID: 11790723
   PubMed Web of Science ®Google Scholar
• Woo JK, Choi Y, Oh SH, Jeong JH, Choi DH, Seo HS, et al. Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway. Oncogene 2012; 31:2187 - 98; http://dx.doi.org/10.1038/onc.2011.410; PMID: 21927028
   PubMed Web of Science ®Google Scholar
• Litvinov SV, Hilkens J. The epithelial sialomucin, episialin, is sialylated during recycling. J Biol Chem 1993; 268:21364 - 71; PMID: 8407976
   PubMed Web of Science ®Google Scholar
• Marti U, Burwen SJ, Wells A, Barker ME, Huling S, Feren AM, et al. Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology 1991; 13:15 - 20; http://dx.doi.org/10.1002/hep.1840130104; PMID: 1988335
   PubMed Web of Science ®Google Scholar
• Boerner JL, Demory ML, Silva C, Parsons SJ. Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. Mol Cell Biol 2004; 24:7059 - 71; http://dx.doi.org/10.1128/MCB.24.16.7059-7071.2004; PMID: 15282306
   PubMed Web of Science ®Google Scholar
• Haley JD, Gullick WJ. EGFR Signaling Networks in Cancer Therapy / edited by John D. Haley, William John Gullick. New York, NY: Humana Press, 2008.
   Google Scholar
• de Oliveira JT, de Matos AJ, Santos AL, Pinto R, Gomes J, Hespanhol V, et al. Sialylation regulates galectin-3/ligand interplay during mammary tumour progression--a case of targeted uncloaking. Int J Dev Biol 2011; 55:823 - 34; http://dx.doi.org/10.1387/ijdb.113359jt; PMID: 22161838
   PubMed Web of Science ®Google Scholar
• Peschard P, Park M. From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 2007; 26:1276 - 85; http://dx.doi.org/10.1038/sj.onc.1210201; PMID: 17322912
   PubMed Web of Science ®Google Scholar
• Horm TMBB, Bitler BG, Broka DM, Louderbough JM, Schroeder JA. MUC1 Drives c-Met-Dependent Migration and Scattering. Mol Cancer Res 2012; In press http://dx.doi.org/10.1158/1541-7786.MCR-12-0296; PMID: 23193156
   PubMed Web of Science ®Google Scholar
• Matsubara D, Ishikawa S, Sachiko O, Aburatani H, Fukayama M, Niki T. Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas. Am J Pathol 2010; 177:2191 - 204; http://dx.doi.org/10.2353/ajpath.2010.100217; PMID: 20934974
   PubMed Web of Science ®Google Scholar
• Li YQ, Yu WH, Ren J, Chen W, Huang L, Kharbanda S, et al. Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res 2003; 1:765 - 75; PMID: 12939402
   PubMed Web of Science ®Google Scholar
• Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7:505 - 16; http://dx.doi.org/10.1038/nrm1962; PMID: 16829981
   PubMed Web of Science ®Google Scholar
• Todorović V, Desai BV, Patterson MJS, Amargo EV, Dubash AD, Yin TF, et al. Plakoglobin regulates cell motility through Rho- and fibronectin-dependent Src signaling. J Cell Sci 2010; 123:3576 - 86; http://dx.doi.org/10.1242/jcs.070391; PMID: 20876660
   PubMed Web of Science ®Google Scholar
• Aktary Z, Chapman K, Lam L, Lo A, Ji C, Graham K, et al. Plakoglobin interacts with and increases the protein levels of metastasis suppressor Nm23-H2 and regulates the expression of Nm23-H1. Oncogene 2010; 29:2118 - 29; http://dx.doi.org/10.1038/onc.2009.495; PMID: 20101217
   PubMed Web of Science ®Google Scholar
• Ahmad R, Alam M, Rajabi H, Kufe D. The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function. J Biol Chem 2012; 287:20866 - 75; http://dx.doi.org/10.1074/jbc.M112.357293; PMID: 22544745
   PubMed Web of Science ®Google Scholar
• Raina D, Ahmad R, Kumar S, Ren J, Yoshida K, Kharbanda S, et al. MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J 2006; 25:3774 - 83; http://dx.doi.org/10.1038/sj.emboj.7601263; PMID: 16888623
   PubMed Web of Science ®Google Scholar
• Ren J, Li Y, Kufe D. Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem 2002; 277:17616 - 22; http://dx.doi.org/10.1074/jbc.M200436200; PMID: 11877440
   PubMed Web of Science ®Google Scholar
• Rajabi H, Ahmad R, Jin C, Kosugi M, Alam M, Joshi MD, et al. MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells. J Biol Chem 2012; 287:10703 - 13; http://dx.doi.org/10.1074/jbc.M111.323311; PMID: 22318732
   PubMed Web of Science ®Google Scholar
• Yuan Z, Wong S, Borrelli A, Chung MA. Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochem Biophys Res Commun 2007; 362:740 - 6; http://dx.doi.org/10.1016/j.bbrc.2007.08.074; PMID: 17764657
   PubMed Web of Science ®Google Scholar
• Bernier AJ, Zhang J, Lillehoj E, Shaw AR, Gunasekara N, Hugh JC. Non-cysteine linked MUC1 cytoplasmic dimers are required for Src recruitment and ICAM-1 binding induced cell invasion. Mol Cancer 2011; 10:93; http://dx.doi.org/10.1186/1476-4598-10-93; PMID: 21798038
   PubMed Web of Science ®Google Scholar
• Pandey P, Kharbanda S, Kufe D. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res 1995; 55:4000 - 3; PMID: 7664271
   PubMed Web of Science ®Google Scholar
• Sahraei M, Roy LD, Curry JM, Teresa TL, Nath S, Besmer D, et al. MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene 2012; 31:4935 - 45; http://dx.doi.org/10.1038/onc.2011.651; PMID: 22266848
   PubMed Web of Science ®Google Scholar
• Singh PK, Wen Y, Swanson BJ, Shanmugam K, Kazlauskas A, Cerny RL, et al. Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res 2007; 67:5201 - 10; http://dx.doi.org/10.1158/0008-5472.CAN-06-4647; PMID: 17545600
   PubMed Web of Science ®Google Scholar
• Julian J, Dharmaraj N, Carson DD. MUC1 is a substrate for gamma-secretase. J Cell Biochem 2009; 108:802 - 15; http://dx.doi.org/10.1002/jcb.22292; PMID: 19711367
   PubMed Web of Science ®Google Scholar
• Leng Y, Cao C, Ren J, Huang L, Chen D, Ito M, et al. Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem 2007; 282:19321 - 30; http://dx.doi.org/10.1074/jbc.M703222200; PMID: 17500061
   PubMed Web of Science ®Google Scholar
• Wei X, Xu H, Kufe D. Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res 2007; 67:1853 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-06-3063; PMID: 17308127
   PubMed Web of Science ®Google Scholar
• Bitler BG, Goverdhan A, Schroeder JA. MUC1 regulates nuclear localization and function of the epidermal growth factor. J Cell Sci 2010; 123:1716 - 23; http://dx.doi.org/10.1242/jcs.062661; PMID: 20406885
   PubMed Web of Science ®Google Scholar
• Lau SK, Shields DJ, Murphy EA, Desgrosellier JS, Anand S, Huang M, et al. EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1. PLoS One 2012; 7:e36753; http://dx.doi.org/10.1371/journal.pone.0036753; PMID: 22586492
   PubMedGoogle Scholar
• Baldus SE, Mönig SP, Huxel S, Landsberg S, Hanisch FG, Engelmann K, et al. MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res 2004; 10:2790 - 6; http://dx.doi.org/10.1158/1078-0432.CCR-03-0163; PMID: 15102686
   PubMed Web of Science ®Google Scholar
• Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011; 30:1449 - 59; http://dx.doi.org/10.1038/onc.2010.526; PMID: 21102519
   PubMed Web of Science ®Google Scholar
• Behrens ME, Grandgenett PM, Bailey JM, Singh PK, Yi CH, Yu F, et al. The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF. Oncogene 2010; 29:5667 - 77; http://dx.doi.org/10.1038/onc.2010.327; PMID: 20697347
   PubMed Web of Science ®Google Scholar
• Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 1998; 4:1449 - 52; http://dx.doi.org/10.1038/4042; PMID: 9846587
   PubMed Web of Science ®Google Scholar
• Bitler BG, Schroeder JA. Anti-cancer therapies that utilize cell penetrating peptides. Recent Pat Anticancer Drug Discov 2010; 5:99 - 108; http://dx.doi.org/10.2174/157489210790936252; PMID: 19961434
   PubMed Web of Science ®Google Scholar
• Bitler BG, Menzl I, Huerta CL, Sands B, Knowlton W, Chang A, et al. Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res 2009; 15:100 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-08-1745; PMID: 19118037
   PubMed Web of Science ®Google Scholar
• Zhang L, Gallup M, Zlock L, Basbaum C, Finkbeiner WE, McNamara NA. Cigarette smoke disrupts the integrity of airway adherens junctions through the aberrant interaction of p120-catenin with the cytoplasmic tail of MUC1. J Pathol 2012; In press http://dx.doi.org/10.1002/path.4070; PMID: 22833523
   PubMed Web of Science ®Google Scholar
• Klinge CM, Radde BN, Imbert-Fernandez Y, Teng Y, Ivanova MM, Abner SM, et al. Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cells. Mol Cancer Ther 2011; 10:2062 - 71; http://dx.doi.org/10.1158/1535-7163.MCT-11-0381; PMID: 21862684
   PubMed Web of Science ®Google Scholar
• Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther 2011; 10:806 - 16; http://dx.doi.org/10.1158/1535-7163.MCT-10-1050; PMID: 21421804
   PubMed Web of Science ®Google Scholar
• Yin L, Kufe D. MUC1-C Oncoprotein Blocks Terminal Differentiation of Chronic Myelogenous Leukemia Cells by a ROS-Mediated Mechanism. Genes Cancer 2011; 2:56 - 64; http://dx.doi.org/10.1177/1947601911405044; PMID: 21643558
   PubMedGoogle Scholar
• Hisatsune A, Nakayama H, Kawasaki M, Horie I, Miyata T, Isohama Y, et al. Anti-MUC1 antibody inhibits EGF receptor signaling in cancer cells. Biochem Biophys Res Commun 2011; 405:377 - 81; http://dx.doi.org/10.1016/j.bbrc.2011.01.029; PMID: 21219855
   PubMed Web of Science ®Google Scholar
• Schettini J, Kidiyoor A, Besmer DM, Tinder TL, Roy LD, Lustgarten J, et al. Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity. Cancer Immunol Immunother 2012; 61:2055 - 65; http://dx.doi.org/10.1007/s00262-012-1264-y; PMID: 22543528
   PubMed Web of Science ®Google Scholar
• Wang L, Chen H, Pourgholami MH, Beretov J, Hao J, Chao H, et al. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One 2011; 6:e24405; http://dx.doi.org/10.1371/journal.pone.0024405; PMID: 21931707
   PubMedGoogle Scholar
• Oei AL, Moreno M, Verheijen RH, Sweep FC, Thomas CM, Massuger LF, et al. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. Int J Cancer 2008; 123:1848 - 53; http://dx.doi.org/10.1002/ijc.23725; PMID: 18661524
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Pietersz GA, Tsibanis A, Tsikkinis A, Drakaki H, Loveland BE, et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. [ISRCTN71711835] Breast Cancer Res 2006; 8:R27; http://dx.doi.org/10.1186/bcr1505; PMID: 16776849
   PubMed Web of Science ®Google Scholar
• Kamata M, Denda-Nagai K, Kubota N, Aida S, Takeda K, Irimura T. Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases. Clin Exp Metastasis 2002; 19:689 - 96; http://dx.doi.org/10.1023/A:1021332932531; PMID: 12553374
   PubMed Web of Science ®Google Scholar
• Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, et al. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci U S A 2012; 109:261 - 6; http://dx.doi.org/10.1073/pnas.1115166109; PMID: 22171012
   PubMed Web of Science ®Google Scholar
• Kovjazin R, Volovitz I, Kundel Y, Rosenbaum E, Medalia G, Horn G, et al. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors. Vaccine 2011; 29:4676 - 86; http://dx.doi.org/10.1016/j.vaccine.2011.04.103; PMID: 21570434
   PubMed Web of Science ®Google Scholar
• McCarthy N. Running a Muc1. Nat Rev Cancer 2012; 12:317; http://dx.doi.org/10.1038/nrc3274
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331:1559 - 64; http://dx.doi.org/10.1126/science.1203543; PMID: 21436443
   PubMed Web of Science ®Google Scholar